177-Lu JH 020002
Alternative Names: 177-Lu-JH020002Latest Information Update: 22 Jan 2024
Price :
$50 *
At a glance
- Originator Bivision Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 22 Dec 2023 Phase-I/II clinical trials in Prostate cancer (Late-stage disease) in China (IV) (NCT06139575)
- 18 Nov 2023 Bivision Pharmaceuticals plans a phase I/II trial for Prostate Cancer (Late-stage disease, Metastatic disease) in December 2023 (NCT06139575)
- 18 Nov 2023 Preclinical trials in Prostate cancer in China (IV)